Strolll provides a platform that combines digital content with the real world through AR glasses to improve conditions for people living with neurological disorders such as Parkinson’s disease, stroke, and Multiple Sclerosis. Led by CEO Jorgen Ellis, the company delivers gamified, clinician‑designed physiotherapy exercises—currently seven games with more in development—to enable personalised, high‑dosage immersive neurorehabilitation. Its solution supports therapy in both in‑clinic and at‑home settings and aims to improve treatment outcomes while reducing staffing requirements and administrative burdens. The company intends to use the funds to accelerate sales and marketing, extend product leadership and expand the regulatory label. Strolll raised £10.35M in a Series A round led by IW Capital. The company is based in Stafford, UK. Strolll develops an AR-based digital therapeutics platform that uses see-through augmented reality glasses to deliver scalable, personalised dual-task training for people with Parkinson’s disease. The platform measures gait and cognitive performance while patients complete simultaneous physical and cognitive challenges, enabling in-clinic and at-home rehabilitation. Strolll emphasizes a therapist-empowering workflow intended to boost patient adherence, elevate outcomes, and reduce administrative burden. As one of few companies using see-through AR glasses rather than VR headsets, the company positions its product as advanced for neuro-rehab implementation. Strolll will integrate Cleveland Clinic’s DART (Dual-task Augmented Reality Treatment) module into its platform as part of the collaboration. DART was developed to address high fall risk during dual-tasking and has been evaluated in a randomized controlled trial, according to Cleveland Clinic investigators. The company says the collaboration supports extending digital therapeutics into patients’ homes and wider clinical availability.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2025